Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 2;2:139. doi: 10.1038/s43856-022-00202-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Line graphs demonstrating significant reductions in anxiety ratings in 14 patients following 4 weeks of treatment with a high-cannabidiol (CBD) study product for anxiety. Significant reductions in anxiety relative to baseline were observed for the (A) Beck Anxiety Inventory (BAI), (B) Overall Anxiety Severity and Impairment Scale (OASIS), (D) and (E) State-Trait Anxiety Inventory (STAI), and (F) Hamilton Anxiety Rating Scale (HAM-A). Additionally, cumulative frequency curves of treatment responders, defined as patients who achieved and maintained clinical improvement of ≥15% reduction of anxiety symptoms on the BAI and OASIS, demonstrated rapid, clinically significant treatment response (C). Most patients achieved and maintained treatment response after 1 week and all patients achieved and maintained treatment response by week 3. The color-shaded areas represent one standard deviation from the mean (A, B, D, E, F) or the proportion of treatment responders (C).